Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?

Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma.

| More on:
bull vs bear

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price could hit a record high this morning after the medical researcher boasted of a “ground breaking” discovery for its drug designed to treat osteoarthritis in the knees. 

According to the company its patented drug Zilosul has been shown to inhibit ‘nerve growth factor’ (NGF) in bone cells in knee osteoarthritis patients and thus reduce pain. It reports that its research has been peer reviewed and published in the international scientific journal PLoS One.

The research also supports Paradigm’s conclusions from its recent Phase II clinical trial into the treatment of pain and cartilage degeneration in knees and supports its regulatory submissions to the U.S. healthcare regulator the FDA. 

Paradigm will need to run a far larger, more expensive, and clinically comprehensive clinical trial into the drug in order to persuade the FDA of its clinical efficacy. 

The biotech also claimed the drug offered a “very attractive commercial opportunity” for ‘big pharma’ to partner with it in funding research and commercialisation. In part it claimed this is because the drug could help meet the need to treat the “opiate addiction” crisis in the US. 

If it can strike a partnership deal with “big pharma” this is likely to be a major positive for the business and stock. 

All this sounds exciting and Paradigm already has a market value around $488 million despite having no material revenues and expensive drug trials ahead of it. Thankfully it did have around $72 million cash on hand as at June 30, 2019. 

As we’re not far from Melbourne Cup Day, Paradigm could be considered one of the ‘favourites’ amongst a field of speccy ASX biotechs looking for eternal glory.

Others include Mesoblast limited (ASX: MSB), Opthea Limited (ASX: OPH), Next Science Ltd (ASX: NXS) and Bionomics Ltd (ASX: BNO). The first three already posting sales and looking worthy of more research for anyone seeking the next biotech blockbuster. 

However, as a word of warning biotech businesses’ share prices can rise for a long time on the rumour or speculation before tumbling spectacularly on the fact.

Along the way different forces are jockeying for position often in possession of different information to turn profits, with any insider selling or unusual volume something to keenly watch for. 

If you’ve done your research on Paradigm then it might be worth a small punt, although I am not a buyer of shares myself. 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Two hands being shaken symbolising a deal.
Mergers & Acquisitions

How many global mega deals involved ASX 200 shares in the first half of 2022?

Deal making among ASX 200 shares helped drive a 25.4% increase in M&A activity in Australia in the first half…

Read more »

Top 10 blank list on chalkboard
Share Market News

Here are the top 10 ASX shares today

Here are your top 10 biggest gainers in the ASX 200 on Wednesday.

Read more »

a sad looking engineer or miner wearing a high visibility jacket and a hard hat stands alone with his head bowed and hand to his forehead as he speaks on a mobile telephone out front of what appears to be an on site work shed.
Resources Shares

Should investors dig the BHP share price in July?

BHP shares are sinking. Is it time to jump on the ASX mining giant?

Read more »

a man peers between two large piles of papers and files with a wide-eyed, wide-mouth look of dread at the amount of work he has to do.
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Wednesday

We take a look at the most traded ASX 200 shares by volume today.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Healthcare Shares

Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here...

Read more »

A man in his 30s holds his computer underneath and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Guess which ASX All Ords shares are serving up 15% gains today

Tech shares continue to lead the way on Wednesday.

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Beach, BHP, Bubs, and Galileo Mining shares are sinking

These ASX shares are under pressure on Wednesday...

Read more »

rising asx share price in food and consumer staples sector represented by happy face made from cut up banana
Share Gainers

Why Domino’s, EML, Talga, and Woolworths shares are pushing higher

These ASX shares are pushing higher on Wednesday...

Read more »